2:02 PM
 | 
May 16, 2018
 |  BC Extra  |  Clinical News

Nektar reports updated response data for immuno-oncology combo

Nektar Therapeutics (NASDAQ:NKTR) reported response data from 60 evaluable patients with solid tumors who were naïve to immunotherapy in the Phase Ib/II PIVOT-02 trial evaluating the company's NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab. The data were released in an abstract ahead of the American Society of Clinical Oncology meeting in Chicago.

NKTR-214 is an immunostimulatory cytokine engineered to selectively activate IL-2 receptor beta chain (CD122; IL2RB) receptors on cytotoxic T cells, resulting in increased PD-1 expression on T cells and NK cells in the tumor microenvironment.

In 23 evaluable patients with stage IV melanoma, first-line treatment with NKTR-214 plus Opdivo led to an overall response rate (ORR) of 52% and a disease control rate (DCR) of 78%. Nektar previously reported that the combination led to a best ORR of 64% in 11 evaluable treatment-naïve melanoma patients (see BioCentury Extra, Nov. 13, 2017).

In 24 evaluable renal cell carcinoma (RCC) patients, first-line treatment with the combination led to an ORR of 54% and a DCR of 79%. In March, the company reported an updated best ORR of 71% in 14 evaluable RCC patients who received NKTR-214 plus Opdivo in the Phase Ib portion of the trial (see BioCentury Extra, March 2).

Nektar also reported data in the ASCO abstract from a handful of patients in the non-small cell lung cancer (NSCLC), urothelial carcinoma and triple-negative breast cancer (TNBC) cohorts of PIVOT-02. In six evaluable NSCLC patients, NKTR-214 plus Opdivo as first- or second-line treatment led to an ORR of 50%. The ORR was 75% in four evaluable urothelial carcinoma who received the combination as first-line treatment and 33% in three evaluable TNBC patients who received the combination as first- or second-line treatment.

The abstract included data as of an early February cut-off.

In February, Nektar partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to develop and commercialize NKTR-214 in combination with the pharma's Opdivo and Opdivo plus the pharma’s Yervoy ipilimumab in select solid tumors. Nektar and BMS plan to begin mid-year two Phase III trials of NKTR-214 plus Opdivo as first-line treatment of RCC and melanoma (see BioCentury, March 2).

Nektar was up $2.40 to $85.80 on Wednesday. The data were released after market close.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD